基线血清睾酮与双相雄激素治疗及恩扎卢胺在随机TRANSFORMER试验中的差异疗效
TRANSFORMER试验事后分析评估基线血清睾酮(T)能否作为转移性去势抵抗性前列腺癌(mCRPC)的治疗选择标志物。该随机试验纳入阿比特龙预处理后患者,分配至双相雄激素治疗(BAT,n=94)或恩扎卢胺(n=101)。结果提示对阿比特龙疗效差且血清T≥20 ng/dL的患者可能优先从BAT而非恩扎卢胺获益,考虑BAT时可将基线睾酮纳入治疗选择过程。
要点
- 对阿比特龙疗效差且基线血清T≥20 ng/dL的mCRPC患者可能优先从BAT而非恩扎卢胺获益。
- TRANSFORMER试验纳入阿比特龙预处理后mCRPC患者,BAT组n=94,恩扎卢胺组n=101。
- 考虑BAT作为治疗选项时,可将基线睾酮纳入治疗选择过程。
核心结论
- 对阿比特龙疗效差且基线血清T≥20 ng/dL的患者可能优先从BAT而非恩扎卢胺获益。
- 考虑BAT作为治疗选项时,可将基线睾酮纳入治疗选择过程。
研究设计与样本
- TRANSFORMER随机试验的事后分析,纳入阿比特龙预处理后的mCRPC患者,分配至BAT(n=94)或恩扎卢胺(n=101)。
主要发现
- 对阿比特龙疗效差且基线血清T≥20 ng/dL的患者可能优先从BAT而非恩扎卢胺获益。
临床怎么用
- 考虑BAT作为治疗选项时,可将基线睾酮纳入治疗选择过程。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bipolar androgen therapy (BAT) is effective in a subset of metastatic castration-resistant prostate cancer (mCRPC) patients. Treatment selection biomarkers are needed due to other therapies that can be equally efficacious. We performed post-hoc analysis to determine whether baseline serum testosterone (T) is a treatment selection marker in the TRANSFORMER study, a randomized trial of abiraterone-pretreated mCRPC patients assigned to BAT (n = 94) or enzalutamide (n = 101). The findings suggest that patients with poor outcomes to abiraterone and serum T ≥ 20 ng/dL may benefit preferentially from BAT over enzalutamide. Baseline testosterone could be considered in the treatment selection process when BAT is an option.
引用
- Kanayama M, Tsai HL, Wang H, et al. Baseline serum testosterone and differential efficacy of bipolar androgen therapy and enzalutamide in the randomized TRANSFORMER trial. Prostate Cancer Prostatic Dis. 2024. PMID: 38714781. doi:10.1038/s41391-024-00844-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。